Clinical trials: Systemic Autoimmune Diseases
Systemic Lupus Erythematosus (SLE)
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE have ongoing disease activity despite treatment with standard of care…
- Trial name
- NCT04058028
- Testing
- Rozibafusp Alfa
- Where
- 147 sites in United States, Argentina and 17 more
- Volunteers
- 244 people
- Sponsor
- Amgen
Vasculitis
Belimumab in Remission of VASculitis
The purpose of this study is to evaluate the efficacy and safety of belimumab, in combination with azathioprine, for the maintenance of remission following a standard induction regimen in patients with Wegener's granulomatosis or…
- Trial name
- BREVAS (NCT01663623)
- Testing
- Belimumab 10 mg/kg, Azathioprine
- Where
- 89 sites in United States, Australia and 18 more
- Volunteers
- 106 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus, Connective Tissue Disease
On Open-Label Study in Participants With Systemic Lupus Erythematosus
The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399 in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).
- Conditions
- Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
- Trial name
- Illuminate-X (NCT01488708)
- Testing
- LY2127399
- Where
- United States
- Volunteers
- 1,518 people
- Sponsor
- Eli Lilly and Company
Systemic Lupus Erythematosus
A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
The purpose of this study is to compare the genotype-based personal prescription of cyclophosphamide with the traditional prescription.
- Trial name
- SLE (NCT01689350)
- Testing
- Genotype Detection
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Systemic Lupus Erythematosus
Triptorelin for Ovary Protection in Childhood Onset Lupus
The purpose of this study is to test the safety of triptorelin when used for the protection of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for systemic lupus erythematosus (SLE; lupus) and to…
- Trial name
- NCT00124514
- Testing
- Triptorelin pamoate
- Where
- 10 sites in United States, Brazil
- Volunteers
- 31 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum
Systemic Lupus Erythematosus
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT03920267
- Testing
- BMS-986165
- Where
- 98 sites in United States, Argentina and 12 more
- Volunteers
- 261 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
PRV-3279-2a Trial in Systemic Lupus
The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid…
- Trial name
- PREVAIL-2 (NCT05087628)
- Testing
- PRV-3279
- Where
- 36 sites in United States, China and 2 more
- Volunteers
- 28 people
- Sponsor
- Provention Bio, a Sanofi Company
ANCA Associated Vasculitis
Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis
ANCA vasculitis is a pauci-immune systemic small vessel vasculitis. The anti-neutrophilic cytoplasmic antibodies (ANCA) are pathogenic and cause disease by activating neutrophils which damage blood vessels.
- Trial name
- NCT03906227
- Testing
- ENUMERATION OF CD5+ B Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
Systemic Lupus Erythematosus
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
- Trial name
- BRAVE II (NCT03616964)
- Testing
- Baricitinib
- Where
- 159 sites in United States, Argentina and 13 more
- Volunteers
- 778 people
- Sponsor
- Eli Lilly and Company
Scleroderma, Systemic, Sclerosis
Scleroderma: Cyclophosphamide or Transplantation
SCOT is a clinical research study designed for people with severe forms of scleroderma. SCOT stands for Scleroderma: Cyclophosphamide Or Transplantation.
- Conditions
- Scleroderma, Systemic, Sclerosis, Autoimmune Disease
- Trial name
- SCOT (NCT00114530)
- Testing
- mHSCT, cyclophosphamide
- Where
- 17 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
IgAN, LN
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
The purpose of this study was to evaluate the safety and tolerability of OMS721 (narsoplimab) in participants with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), Membranous Nephropathy (MN), and Complement Component 3…
- Conditions
- IgAN, LN, MN, C3G
- Trial name
- NCT02682407
- Testing
- OMS721 (narsoplimab)
- Where
- 12 sites in United States, Hong Kong
- Volunteers
- 31 people
- Sponsor
- Omeros Corporation
Systemic Lupus Erythematosus
A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.
The purpose of the study is to evaluate the safety and tolerability of MEDI-545 in Japanese adult SLE patients. This will be done by collecting the data from 3 cohorts of IV doses and 1 cohort of SC doses.
- Trial name
- NCT01031836
- Testing
- MEDI-545, MEDI-545 600
- Where
- 7 sites in Japan
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus (SLE)
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
- Trial name
- NCT02804763
- Testing
- Dapirolizumab pegol (DZP)
- Where
- 71 sites in United States, Bulgaria and 11 more
- Volunteers
- 182 people
- Sponsor
- UCB Biopharma S.P.R.L.
HIV Infections, Systemic Lupus Erythematosus
Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
The purpose of this study is to evaluate the breadth and potency of HIV-1 neutralizing antibody (nAb) responses and examine the safety and tolerability of an HIV gp120 protein vaccine (AIDSVAX® B/E) in HIV-uninfected adults…
- Trial name
- NCT03618056
- Testing
- AIDSVAX® B/E
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- EMBODY2 (NCT01261793)
- Testing
- Epratuzumab
- Where
- 133 sites in United States, Brazil and 14 more
- Volunteers
- 791 people
- Sponsor
- UCB Pharma
Systemic Lupus Erythematosus
Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
This study will assess the effect of a 24-week withdrawal followed by a 28-week reintroduction of belimumab 10 mg/kg plus standard of care medications in subjects with stable low systemic lupus erythematosus (SLE) disease…
- Trial name
- NCT02119156
- Testing
- Belimumab
- Where
- 20 sites in United States, China and 2 more
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Lupus Nephritis
Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)
Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).
- Trial name
- NCT05540665
- Testing
- Daxdilimab
- Where
- 52 sites in United States, Argentina and 10 more
- Volunteers
- 19 people
- Sponsor
- Amgen
Interstitial Lung Disease, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
The purpose of this study is to investigate the clinical features and long-term outcome of anti-neutrophil cytoplasmic antibody (ANCA)-positive interstitial lung disease (ILD) and assess the difference between microscopic…
- Trial name
- NCT04413149
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Systemic Lupus Erythematosus
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
The purpose of this study is to determine the ability of XmAb5871 to maintain Systemic Lupus Erythematosus (SLE) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy
- Trial name
- NCT02725515
- Testing
- XmAb5871
- Where
- 23 sites in United States
- Volunteers
- 105 people
- Sponsor
- Xencor, Inc.